Cited by 158Cell death mechanisms and regulationMitochondrial Function and PathologyPharmacological Receptor Mechanisms and Effects

Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction

Open access
Ben-Hail, Danya, Begas-Shvartz, Racheli, Shalev, Moran, Shteinfer-Kuzmine, Anna, Gruzman, Arie, Reina, Simona, De Pinto, Vito, Shoshan-Barmatz, Varda·2016·Journal of Biological Chemistry

Abstract

Apoptosis is thought to play a critical role in several pathological processes, such as neurodegenerative diseases ( i.e. Parkinson's and Alzheimer's diseases) and various cardiovascular diseases. Despite the fact that apoptotic mechanisms are well defined, there is still no substantial therapeutic strategy to stop or even slow this process. Thus, there is an unmet need for therapeutic agents that are able to block or slow apoptosis in neurodegenerative and cardiovascular diseases. The outer mitochondrial membrane protein voltage-dependent anion channel 1 (VDAC1) is a convergence point for a variety of cell survival and death signals, including apoptosis. Recently, we demonstrated that VDAC1 oligomerization is involved in mitochondrion-mediated apoptosis. Thus, VDAC1 oligomerization represents a prime target for agents designed to modulate apoptosis. Here, high-throughput compound screening and medicinal chemistry were employed to develop compounds that directly interact with VDAC1 and prevent VDAC1 oligomerization, concomitant with an inhibition of apoptosis as induced by various means and in various cell lines. The compounds protected against apoptosis-associated mitochondrial dysfunction, restoring dissipated mitochondrial membrane potential, and thus cell energy and metabolism, decreasing reactive oxidative species production, and preventing detachment of hexokinase bound to mitochondria and disruption of intracellular Ca 2+ levels. Thus, this study describes novel drug candidates with a defined mechanism of action that involves inhibition of VDAC1 oligomerization, apoptosis, and mitochondrial dysfunction. The compounds VBIT-3 and VBIT-4 offer a therapeutic strategy for treating different diseases associated with enhanced apoptosis and point to VDAC1 as a promising target for therapeutic intervention.

Integrity signals

Registry

Crossref · 10.1074/jbc.m116.744284

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ben-Hail, D., Begas-Shvartz, R., Shalev, M., Shteinfer-Kuzmine, A., Gruzman, A., Reina, S., De Pinto, V., & Shoshan-Barmatz, V.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • Bar-Ilan University (IL)
  • University of Catania (IT)
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2016-11
Volume
291
Issue
48
Pages
24986-25003
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2529946706
Cited by
158
References
92
Citations by year
2026: 24 · 2025: 33 · 2024: 19 · 2023: 20 · 2022: 9 · 2021: 12 · 2020: 12 · 2019: 8 · 2018: 8 · 2017: 13
FWCI
5.03
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pharmacological Receptor Mechanisms and Effects
Keywords
VDAC1, apoptosis inhibition, mitochondrial dysfunction, VDAC1 oligomerization, mitochondrial outer membrane, mitochondrial membrane potential, reactive oxygen species, hexokinase, intracellular calcium, neurodegenerative diseases, cardiovascular disease, drug candidates
MeSH terms
Animals, Energy Metabolism, HeLa Cells, Humans, Mitochondria, Apoptosis, Mice, Knockout, Calcium Signaling, Voltage-Dependent Anion Channel 1, Mice, Rats, Protein Multimerization, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review